Electromedical Technologies, Inc. (OTC: ELCQ) (the “Company), the developer and manufacturer of WellnessPro Plus™ therapeutic medical device, is pleased to provide this corporate update summarizing its business to date, and its goals for 2020.
The Company develops and manufactures proprietary medical devices targeting physical pain relief. The Company’s flagship product is the WellnessPro Plus™, developed in 2007. The WellnessPro Plus™ is a portable device designed to deliver localized pain relief, supplied by its distribution of calibrated electrical energy pulses.
The Company’s mission is to develop, market and raise awareness of using electronic pulse therapies as a possible effective replacement or possible complement to current drug therapies targeting pain relief.
The Company’s proprietary technology in the WellnessPro Plus™ is based on its unique energy delivery system called DeepPulse™. DeepPulse™ delivers a low voltage current to treat localized pain, and the Company believes that it provides longer lasting and more effective pain relief than many drugs and other products on the market.
The WellnessPro Plus™ received FDA clearance on July 6, 2007, as a Class II Medical Device, pursuant to the Company’s FDA clearance granted under section 510(K). The intended use of the WellnessPro Plus™ is for the treatment chronic intractable and acute pain, and as an adjunctive treatment for post-surgical and post-traumatic acute pain. The WellnessPro Plus™ is also qualified to be sold and used in Mexico.
The WellnessPro Plus™ was found to meet device safety standards for Radiated Emissions, Electrostatic Discharge, Radiated Immunity and device safety.
Today, many patients use the WellnessPro Plus™ in a variety of settings by healthcare professionals, athletes, coaches and others.
Commenting on the WellnessPro Plus™, the Company’s President and Principal Executive Officer, Matthew Wolfson, observed:
“A new era and a new category of medicine is emerging in the way we treat chronic pain. By learning to read and correct the electrical signals that travel between the brain and the body’s organs, we believe that a whole new frontier in treating chronic and acute pain will become reality in the not too distant future. By using energy, frequency and vibration, we want to unlock the body’s natural ability to achieve wellness, better health and a better quality of life. The WellnessPro Plus™ device provides variable and rotating frequencies that we believe triggers endorphin release, which helps to relieve chronic and acute pain without the use of drugs.”
The Company’s 2019 Achievements
The Company completed Regulation A+ Tier II offering; filed 15C-211 with FINRA to commence trading; and listed on the OTC Markets Pink Tier under ticker Symbol “ELCQ.” The Company completed an independent audit of its financials and filed a registration statement with the Securities and Exchange Commission on November 12, 2019, and is working on addressing comments from the Commission, with the goal of becoming a fully reporting company under the Securities Act.
The Company’s Goals for 2020
The Company is actively engaged in research and development efforts on a new device it is calling the “WellnessPro Pod.” The Company envisions this device to provide more portability and features. The Company’s research and development’s goals for the “WellnessPro Pod” will be to expand the therapeutic uses for the Company’s technology, and to determine whether its technology may be helpful in other possible areas of treatment, such as PTSD, insomnia, depression, and anxiety. The Company also intends to pursue research and development to incorporate laser technology into its products that may allow the Company to enter the cosmetic applications market.
The Company also intends to extend its marketing outreach to wellness centers, targeting venues with significant patient traffic. The Company also expects to qualify its products for use in the European Union and Canada, further expanding its available markets.
The FDA’s issuance of a 510(k) clearance as a Class II Medical Device does not mean that FDA has made a determination that the Company’s device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.
This news release contains “forward-looking statements,” which are not purely historical and may include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs, and results of new business opportunities and words such as “anticipate,” “seek,” “intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our Form S1, and other periodic reports filed from time to time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.
SOURCE Electromedical Technologies, Inc.
Village Farms Opts to Receive $5.94 Million Cash Refund from Pure Sunfarms
Village Farms International, Inc. (“Village Farms“) (TSX: VFF; Nasdaq: VFF) today announced that it has opted to receive a $5.94 million cash refund from Pure Sunfarms Corp. (“Pure Sunfarms“) relating to an additional equity contribution that Village Farms made to Pure Sunfarms on November 19, 2019 (the “VF Additional Equity Contribution“).
As previously disclosed by Emerald Health Therapeutics, Inc. (“Emerald“), it has been disputing Village Farms’ ability to make the VF Additional Equity Contribution of $5.94 million, as well as the cancellation of 5,940,000 common shares of Pure Sunfarms placed in escrow pending payment by Emerald of its related $5.94 million equity contribution, following its failure to make its required equity contribution to Pure Sunfarms on November 1, 2019. In an effort to narrow the issues in dispute and accelerate the resolution of this shareholder dispute, Village Farms decided to unwind the VF Additional Equity Contribution, which has now been completed, with Pure Sunfarms providing Village Farms with the $5.94 million cash refund. The $5.94 million cash refund to Village Farms also eliminates the costs and delays involved in obtaining an independent appraisal of Pure Sunfarms that resulted from the VF Additional Equity Contribution.
Village Farms continues to seek the cancellation of 5,940,000 common shares of Pure Sunfarms that were placed in escrow pending payment by Emerald of its related equity contribution (the “Emerald Share Cancellation“), which was not made as required. It is Village Farms’ position that the Emerald Share Cancellation is expressly provided for in the applicable legal agreements.
“Due to the arbitration process related to the Emerald Share Cancellation taking significantly longer than originally anticipated, and with the resulting number of incremental shares for our $5.94 million equity contribution unknown, we decided to reduce the number of items in dispute in an effort to bring the matter to resolution sooner for Village Farms and its shareholders,” said Michael DeGiglio, CEO, Village Farms. “In addition, as a result of the $5.94 million cash refund to Village Farms, we anticipate that Pure Sunfarms may call for additional equity contributions by each of Village Farms and Emerald.”
If Village Farms is successful in the arbitration and Emerald’s escrowed shares are cancelled, Village Farms would own 53.5% of Pure Sunfarms and Emerald would own 46.5% effective as of November 19, 2019. Village Farms expects a decision from the arbitration panel during the second half of 2020.
Certain statements contained in this press release constitute forward-looking information within the meaning of applicable securities laws (“forward-looking statements”). Forward-looking statements may relate to Village Farms’ future outlook or financial position and anticipated events or results and may include statements regarding the financial position, business strategy, budgets, litigation, projected production, projected costs, capital expenditures, financial results, taxes, plans and objectives of or involving Village Farms and Pure Sunfarms. Particularly, statements regarding future results, performance, achievements, prospects or opportunities for Village Farms, Pure Sunfarms, the greenhouse vegetable industry or the cannabis and hemp industries are forward-looking statements. In some cases, forward-looking information can be identified by such terms as “outlook”, “may”, “might”, “will”, “could”, “should”, “would”, “occur”, “expect”, “plan”, “anticipate”, “believe”, “intend”, “estimate”, “predict”, “potential”, “continue”, “likely”, “schedule”, “objectives”, or the negative or grammatical variation thereof or other similar expressions concerning matters that are not historical facts.
Although the forward-looking statements contained in this press release are based upon assumptions that management believes are reasonable based on information currently available to management, there can be no assurance that actual results or events will be consistent with these forward-looking statements. Forward-looking statements necessarily involve known and unknown risks and uncertainties, many of which are beyond Village Farms’ control, that may cause Village Farms’ or the industry’s actual results, performance, achievements, prospects and opportunities in future periods to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things, the factors contained in Village Farms’ filings with U.S. and Canadian securities regulators, including as detailed in Village Farms’ annual information form and management’s discussion and analysis for the year-ended December 31, 2018 and for the three and nine-month periods ended September 30, 2019.
When relying on forward-looking statements to make decisions, Village Farms cautions readers not to place undue reliance on these statements, as forward-looking statements involve significant risks and uncertainties and should not be read as guarantees of future results, events, performance, achievements, prospects and opportunities. The forward-looking statements made in this press release only relate to events or information as of the date on which the statements are made in this press release. Except as required by law, Village Farms undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Village Farms International, Inc.
Canada House Wellness Group Announces Results of Annual General Meeting and Issuance of Stock Options
Canada House Wellness Group Inc. (CSE: CHV) (“Canada House” or the “Company“) is pleased to announce the results of the company’s Annual General Meeting of shareholders that was held in Fredericton, New Brunswick on Thursday, December 19, 2019, where two business items were presented and approved by the shareholders in attendance.
The Directors of the Company that were nominated at the meeting – Norman Betts, Chris Churchill-Smith, Shawn Graham, Gaetan Lussier, and Dennis Moir – were elected to hold office until the next Annual General Meeting of Shareholders, or until their successors are elected or appointed.
In addition, Ernst & Young LLP were appointed as auditors of the Company for the following year and the Directors were authorized to fix their remuneration.
The business summary presented at the Annual General Meeting is available on the Investor Centre section of Canada House’s website at https://canadahouse.ca.
The Company is also pleased to announce the immediate granting of 500,000 stock options to senior employees and advisors at an exercise price of $0.05 and with a term of 5-years. The grant was made in accordance with the Company’s stock option plan and the policies of the Canadian Securities Exchange.
SOURCE Canada House Wellness Group Inc.
Canopy Growth Revises Beverage Launch Timeline
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED), (NYSE: CGC) submitted its final documentation for its beverage facility to Health Canada in late June 2019 and subsequently received the licence in late November 2019. In the seven weeks since receiving the licence, the Company has made meaningful progress towards scaling the production process for its cannabis beverages from lab scale to commercial scale.
Management remains very confident in the underlying beverage science and in its ability to scale production and deliver high quality, differentiated cannabis beverages to the market. However, the scaling process is not complete, and the Company is extending its to-market date while the internal teams complete the final steps.
“Canopy has had seven weeks to work with THC in the brand new beverage facility to scale processes and IP it has developed in the R&D environment,” said David Klein, CEO, Canopy Growth. “In order to deliver products that meet our customer’s high standards we are electing to revise the launch date while we work through the final details.”
Cannabis beverages have disruptive power and in time, may introduce new consumers to the cannabis category. Canopy does not believe this delay will have a material impact on its FY20 revenue.
The Company intends to provide an update with the release of its Q3 FY20 financial results.
Here’s to Future (Cannabis Category) Growth.
SOURCE Canopy Growth Corporation
Cannabis2 weeks ago
Flora Enters Into Agreement to Acquire Kasa Wholefoods Company S.A.S.
Cannabis2 weeks ago
HEXO CORP. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against HEXO Corp.
Cannabis4 weeks ago
Hemp, Inc. CEO, Bruce Perlowin, Featured In Havasu News Coverage About Kins Communities
Cannabis3 weeks ago
Top Strike Announces 2020 Second Quarter Financial Results and Provides Corporate Activity and Update
Cannabis3 weeks ago
MediPharm Labs Receives Licence Amendment to Permit Use of Expanded Canadian Facility for Private Label and White Label Production and R&D
Cannabis3 weeks ago
Hemp, Inc. Applauds USDA’s New Insurance Option For Hemp
Cannabis3 weeks ago
MJ Holdings Shareholder Update 2019
Cannabis4 weeks ago
HEXO CORP. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against HEXO Corp.